Interestingly, the XPG gene promoter contains a putative CpG island and analysis of specimens obtained from ovarian cancer patients identified DNA methylation in ~20% of the tumor samples, but not in the matched blood DNA [62], suggesting that XPG expression may be influenced by epigenetic mechanisms in tumors. This evidence concerns the gene ERCC5 and ovarian carcinoma.